Nuo Therapeutics, Inc. (AURX) Research

Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.

Market snapshot

Symbol
AURX
Price
$0.90
Day change
0.00%
Market cap
$43.8M
P/E ratio
-18.32x
52-week range
0.8415-3.23
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 9 days
Analyst price target
$3.00

Peer companies

  • Green Growth Brands Inc. (GGBXF)
  • Hofseth BioCare ASA (HOFBF)
  • Imugene Limited (IUGNF)
  • Kintor Pharmaceutical Limited (KNTPF)
  • Satellos Bioscience Inc. (MSCLF)
  • Paradigm Biopharmaceuticals Limited (PBIGF)
  • Poolbeg Pharma PLC (POLBF)
  • AVITA Medical, Inc. (RCEL)

Recent insider activity

  • JORDEN DAVID EMERSON — A-Award (13245 shares) on 2026-06-05
  • Pittman Scott M. — A-Award (17450 shares) on 2026-05-29
  • Pittman Scott M. — D-Return (36750 shares) on 2026-05-29
  • Pittman Scott M. — D-Return (7516 shares) on 2026-05-29
  • Pittman Scott M. — A-Award (17500 shares) on 2026-05-29

Open Nuo Therapeutics, Inc. (AURX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.